| |
Number of studies included
|
Vaccine exposure group (total, n)
|
Vaccine exposure group (SA, n)
|
Control group (total, n)
|
Control group (SA, n)
|
RR
|
95% CI
|
I
2
|
RD (%)
|
95% CI (%)
|
I
2
|
|---|
|
2vHPV (Pre-90 days to pregnancy end)
|
|
Data source
|
|
Clinical Trials base
|
2
|
846
|
121
|
3676
|
464
|
1.16
|
0.88–1.55
|
42.7
|
2.0
|
−1.7-5.7
|
43.5
|
|
Database
|
1
|
330
|
34
|
632
|
57
|
1.14
|
0.76–1.71
|
–
|
1.3
|
−2.7-5.3
|
–
|
|
Adjusted data or not
|
|
Adjusted a
|
2
|
711
|
84
|
3859
|
471
|
1.03
|
0.90–1.19
|
0.0
|
–
|
–
|
–
|
|
Unadjusted
|
1
|
465
|
71
|
449
|
50
|
1.37
|
0.98–1.39
|
–
|
–
|
–
|
–
|
|
4vHPV (Pre-45 days to pregnancy end)
|
|
Data source
|
|
Clinical trials base
|
2
|
213
|
31
|
1486
|
180
|
0.85
|
0.57–1.27
|
0.0
|
−2.2
|
−7.8-3.4
|
0.0
|
|
Database
|
2
|
2344
|
207
|
2771
|
209
|
0.89
|
0.72–1.09
|
20.2
|
−1.0
|
−2.7-0.7
|
0.0
|
|
Adjusted data or not
| | | | | | | | | | | |
|
Adjusted a
|
2
|
2344
|
207
|
2771
|
209
|
1.06
|
0.85–1.32
|
13.7
|
–
|
–
|
–
|
|
Unadjusted
|
2
|
213
|
31
|
1486
|
180
|
0.85
|
0.57–1.27
|
0.0
|
–
|
–
|
–
|
- a adjusted by age at conception, 2vHPV bivalent HPV vaccine, 4vHPV quadrivalent HPV vaccine, LMP Last menstrual period, SA Spontaneous abortion, RR Relative risk, RD Risk difference
